DE602004027244D1 - Therapeutisches mittel für ein weichteilsarkom - Google Patents

Therapeutisches mittel für ein weichteilsarkom

Info

Publication number
DE602004027244D1
DE602004027244D1 DE602004027244T DE602004027244T DE602004027244D1 DE 602004027244 D1 DE602004027244 D1 DE 602004027244D1 DE 602004027244 T DE602004027244 T DE 602004027244T DE 602004027244 T DE602004027244 T DE 602004027244T DE 602004027244 D1 DE602004027244 D1 DE 602004027244D1
Authority
DE
Germany
Prior art keywords
compound
formula
arkom
soft
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004027244T
Other languages
English (en)
Inventor
Tatsuo Ito
Toshifumi Ozaki
Mamoru Ouchida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of DE602004027244D1 publication Critical patent/DE602004027244D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602004027244T 2003-06-27 2004-06-25 Therapeutisches mittel für ein weichteilsarkom Expired - Lifetime DE602004027244D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003183643 2003-06-27
PCT/JP2004/009371 WO2005000332A2 (en) 2003-06-27 2004-06-25 Therapeutic agent for soft tissue sarcoma

Publications (1)

Publication Number Publication Date
DE602004027244D1 true DE602004027244D1 (de) 2010-07-01

Family

ID=33549590

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004027244T Expired - Lifetime DE602004027244D1 (de) 2003-06-27 2004-06-25 Therapeutisches mittel für ein weichteilsarkom

Country Status (14)

Country Link
US (2) US7056883B2 (de)
EP (2) EP1638541B1 (de)
JP (1) JP4661782B2 (de)
AT (1) ATE468113T1 (de)
CA (1) CA2529840A1 (de)
CY (1) CY1113534T1 (de)
DE (1) DE602004027244D1 (de)
DK (1) DK2238982T3 (de)
ES (2) ES2341771T3 (de)
MX (1) MXPA06000013A (de)
PL (1) PL2238982T3 (de)
PT (1) PT2238982E (de)
SI (1) SI2238982T1 (de)
WO (1) WO2005000332A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
MXPA04009761A (es) * 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
WO2004074478A1 (ja) * 2003-02-19 2004-09-02 Astellas Pharma Inc. ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
WO2005030239A2 (en) * 2003-09-25 2005-04-07 Astellas Pharma Inc. Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
US20060040575A1 (en) * 2004-08-18 2006-02-23 Kelleher Karen A Reflective printing on flame resistant fabrics
EP1715334A1 (de) * 2005-04-22 2006-10-25 Adamant Technologies SA Verfahren unter Verwendung eines Elektrochemischen Sensors und Elektroden, die diesen Sensor bilden
NZ548087A (en) 2005-04-29 2010-10-29 Tomizo Yamamoto Rubber or resin foam containing zirconium or germanium
GB0511266D0 (en) 2005-06-02 2005-07-13 Trust Chemical compounds
KR100809410B1 (ko) * 2005-07-06 2008-03-05 주식회사 브레인가드 줄기세포 분화 유도용 조성물 및 그의 용도
CA2615105A1 (en) 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2618439A1 (en) * 2005-08-12 2007-02-22 Astellas Pharma Inc. Technique for stabilization of yw753 reparation
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
GB0518720D0 (en) * 2005-09-14 2005-10-19 Hamlet Pharma Ab Therapeutic combination
AU2006311820A1 (en) * 2005-11-04 2007-05-18 Merck Sharp & Dohme Corp. Methods of using SAHA and erlotinib for treating cancer
US20070117815A1 (en) * 2005-11-04 2007-05-24 James Pluda Method of treating cancers with SAHA and pemetrexed
EP1942884A4 (de) * 2005-11-04 2010-01-06 Merck & Co Inc Verfahren zur behandlung von krebs mit saha, carboplatin und paclitaxel und andere kombinationstherapien
CA2630216A1 (en) * 2005-11-18 2007-05-31 Gloucester Pharmaceuticals, Inc. Metabolite derivatives of the hdac inhibitor fk228
EP2012801A4 (de) 2006-04-24 2009-08-05 Gloucester Pharmaceuticals Inc Gemcitabin-kombinationstherapie
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
JP2010509221A (ja) * 2006-11-03 2010-03-25 ユニバーシテイ・オブ・メリーランド，ボルテイモア 多発性骨髄腫を治療するためにｓａｈａおよびボルテゾミブを使用する方法
EP2450049A1 (de) * 2006-12-29 2012-05-09 Gloucester Pharmaceuticals, Inc. Tumorbehandlung auf der basis von romidepsin
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
CA2676387A1 (en) * 2007-01-23 2008-07-31 Gloucester Pharmaceuticals, Inc. Combination therapy
CN103108648A (zh) 2010-07-12 2013-05-15 细胞基因公司 罗米地辛固体形式及其用途
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
JP6170946B2 (ja) * 2012-01-12 2017-07-26 セルジーン コーポレイション ロミデプシン製剤及びその使用
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
US9410943B2 (en) 2013-03-14 2016-08-09 The Board Of Trustees Of The Leland Stanford Junior University Methods, compositions and screens for therapeutics for the treatment of synovial sarcoma
US20160199323A1 (en) * 2013-08-22 2016-07-14 Vanda Pharmaceuticals, Inc. Cancer treatment
JP2016533364A (ja) * 2013-10-18 2016-10-27 エピザイム，インコーポレイティド 癌を処置する方法
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
WO2016003789A1 (en) * 2014-07-03 2016-01-07 Imclone Llc Combination therapy
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
JP2021512167A (ja) 2018-01-30 2021-05-13 フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 障害を治療するための方法及び化合物
US20230066136A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155225A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60149520A (ja) * 1984-01-13 1985-08-07 Ajinomoto Co Inc 抗腫瘍剤
JPS61176523A (ja) 1985-01-30 1986-08-08 Teruhiko Beppu 制癌剤
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5653997A (en) * 1991-02-28 1997-08-05 Parfums Christian Dior Antiallergic cosmetic or pharmaceutical composition
US5700811A (en) * 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
DE4137540A1 (de) * 1991-11-14 1993-05-19 Steigerwald Arzneimittelwerk Verwendung von praeparaten der curcuma-pflanzen
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
IN188720B (de) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
ES2206195T3 (es) * 1999-03-03 2004-05-16 Eurovita A/S Productos farmaceuticos, suplementos alimentarios y composiciones cosmeticas que comprenden un acido graso y jengibre.
ES2282751T3 (es) 1999-12-08 2007-10-16 Cyclacel Pharmaceuticals, Inc. Uso de depsipeptidos y sus congeneres como inmunodepresores para tratar una enfermedad infecciosa, una enfermedad autoinmunitaria, reacciones alergicas o una enfermedad cutanea hiperproliferativa.
DE60137932D1 (de) * 2000-07-17 2009-04-23 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
US6613534B2 (en) * 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
AR035455A1 (es) * 2001-04-23 2004-05-26 Hoffmann La Roche Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
JP4238728B2 (ja) * 2001-08-21 2009-03-18 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
EP1501489A4 (de) * 2002-04-15 2007-11-21 Sloan Kettering Inst Cancer Kombinationstherapie zur behandlung von krebs
CA2433479A1 (en) * 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US8299126B2 (en) * 2003-02-27 2012-10-30 Leonard A. Cohen Treatment of canine hemangiosarcoma with a histone deacetylase inhibitor
US20050020557A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors

Also Published As

Publication number Publication date
EP1638541A2 (de) 2006-03-29
DK2238982T3 (da) 2013-01-28
EP1638541B1 (de) 2010-05-19
EP2238982B8 (de) 2013-01-16
ES2341771T3 (es) 2010-06-28
JP4661782B2 (ja) 2011-03-30
ES2397079T3 (es) 2013-03-04
PL2238982T3 (pl) 2013-03-29
CY1113534T1 (el) 2016-06-22
ATE468113T1 (de) 2010-06-15
EP2238982B1 (de) 2012-10-17
EP2238982A2 (de) 2010-10-13
WO2005000332A2 (en) 2005-01-06
SI2238982T1 (sl) 2013-01-31
US20050107290A1 (en) 2005-05-19
CA2529840A1 (en) 2005-01-06
JP2007521259A (ja) 2007-08-02
MXPA06000013A (es) 2006-03-21
WO2005000332A3 (en) 2005-03-24
EP2238982A3 (de) 2011-03-02
US20060223747A1 (en) 2006-10-05
US7056883B2 (en) 2006-06-06
PT2238982E (pt) 2013-01-22

Similar Documents

Publication Publication Date Title
DE602004027244D1 (de) Therapeutisches mittel für ein weichteilsarkom
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
WO2005063745A3 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
TW200728307A (en) Novel spirochromanone derivatives
ZA200600343B (en) Substituted 2-aminotetralin for the treatment of depression
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
DE60329001D1 (en) 8-hydroxychinolinderivate
MX2007013624A (es) Inhibidores de proteina cinasa.
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
DE602007014186D1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
MX2007014920A (es) Politerapia que comprende diarilureas para el tratamiento de enfermedades.
NO20075111L (no) Farmasoytisk sammensetning
TW200722081A (en) New therapeutic combinations for the treatment or prevention of depression
EP2639229A3 (de) Thiazolderivate und deren Verwendung als VAP-1-Hemmer
TW200639159A (en) Treatment of pain
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
EP2481428A3 (de) MMP-Aktivierte Gefässschädigende Mittel
WO2007079915A3 (en) Use of triazine derivatives for the manufacture of a medicament having a cicatrising or angiogenic effect
MX2007013305A (es) Nuevas tiazolidinonas sin nitrogeno basico, su produccion y su uso como agentes farmaceuticos.
BRPI0513549A (pt) composições farmacêuticas para o tratamento de leishmaniose

Legal Events

Date Code Title Description
8364 No opposition during term of opposition